Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP, Schwarze JE, Verpillat P, Lispi M, Fischer R, Hayward B, Chuderland D, D'Hooghe T, Krussel JS. Bielfeld AP, et al. Among authors: lispi m. Reprod Biomed Online. 2023 Nov 12;48(6):103725. doi: 10.1016/j.rbmo.2023.103725. Online ahead of print. Reprod Biomed Online. 2023. PMID: 38593745 Free article.
Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP, Schwarze JE, Verpillat P, Lispi M, Fischer R, Hayward B, Chuderland D, D'Hooghe T, Krussel JS. Bielfeld AP, et al. Among authors: lispi m. Best Pract Res Clin Obstet Gynaecol. 2023 Jul;89:102350. doi: 10.1016/j.bpobgyn.2023.102350. Epub 2023 May 11. Best Pract Res Clin Obstet Gynaecol. 2023. PMID: 37320996 Free article. Review.
Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ, Mol BW, Longobardi S, Orvieto R, Venetis CA, Lispi M, Storr A, D'Hooghe T. Chua SJ, et al. Among authors: lispi m. Reprod Biol Endocrinol. 2021 Apr 2;19(1):51. doi: 10.1186/s12958-021-00727-y. Reprod Biol Endocrinol. 2021. PMID: 33794909 Free PMC article.
Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Bühler K, Roeder C, Schwarze JE, Lispi M, Allignol A, Falla E, Lukyanov V, D Hooghe T, Fischer R. Bühler K, et al. Among authors: lispi m. Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):188-202. doi: 10.1016/j.bpobgyn.2022.02.002. Epub 2022 Feb 16. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35304097 Free article.
Comparison between follitropin-delta and follitropin-alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!
Montenegro Gouveia S, Lispi M, D'Hooghe TM. Montenegro Gouveia S, et al. Among authors: lispi m. Reprod Biomed Online. 2022 Sep;45(3):623-624. doi: 10.1016/j.rbmo.2022.03.034. Epub 2022 Apr 9. Reprod Biomed Online. 2022. PMID: 35863940 No abstract available.
Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.
Strezsak V, Allignol A, Bühler K, Fischer R, Hubbard J, Longobardi S, Lispi M, Schertz J, Verpillat P. Strezsak V, et al. Among authors: lispi m. Gynecol Obstet Invest. 2023;88(4):214-225. doi: 10.1159/000530360. Epub 2023 Jun 27. Gynecol Obstet Invest. 2023. PMID: 37369184 Free PMC article.
Reduced FSH and LH action: implications for medically assisted reproduction.
Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, Simoni M, Raine-Fenning N, Crépieux P, Kol S, Rochira V, D'Hooghe T, Humaidan P. Bosch E, et al. Among authors: lispi m. Hum Reprod. 2021 May 17;36(6):1469-1480. doi: 10.1093/humrep/deab065. Hum Reprod. 2021. PMID: 33792685 Free PMC article. Review.
Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.
Koloda Y, Korsak V, Rozenson O, Anshina M, Sagamonova K, Baranov I, Yakovenko S, D'Hooghe T, Ershova A, Lispi M. Koloda Y, et al. Among authors: lispi m. Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):134-148. doi: 10.1016/j.bpobgyn.2022.01.009. Epub 2022 Feb 2. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35216907 Free article.
49 results